

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>FS Development Holdings, LLC</u> (Last) (First) (Middle) C/O FS DEVELOPMENT CORP 600 MONTGOMERY STREET, SUITE 4500 (Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Gemini Therapeutics, Inc. /DE [GMTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Director by Deputization
	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/05/2021		A ⁽¹⁾		1,500,000	A	\$10	1,500,000	D ⁽²⁾	
Common Stock	02/05/2021		C ⁽³⁾		2,928,750	A	\$0	2,928,750	D ⁽²⁾	
Common Stock								441,500	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Common Stock	\$0	02/05/2021		C ⁽³⁾			2,928,750	(3)	(3)	Common Stock	2,928,750	\$0	0	D ⁽²⁾	

1. Name and Address of Reporting Person*
FS Development Holdings, LLC
 (Last) (First) (Middle)
 C/O FS DEVELOPMENT CORP
 600 MONTGOMERY STREET, SUITE 4500
 (Street)
 SAN FRANCISCO CA 94111
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Foresite Capital Fund V, L.P.
 (Last) (First) (Middle)
 C/O FS DEVELOPMENT CORP
 600 MONTGOMERY STREET, SUITE 4500
 (Street)
 SAN FRANCISCO CA 94111
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Foresite Capital Management V, LLC
 (Last) (First) (Middle)
 C/O FS DEVELOPMENT CORP
 600 MONTGOMERY STREET, SUITE 4500
 (Street)

SAN FRANCISCO	CA	94111
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Foresite Capital Opportunity Fund V, L.P.		
(Last)	(First)	(Middle)
C/O FS DEVELOPMENT CORP		
600 MONTGOMERY STREET, SUITE 4500		
(Street)		
SAN FRANCISCO	CA	94111
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Foresite Capital Opportunity Management V, LLC		
(Last)	(First)	(Middle)
C/O FS DEVELOPMENT CORP		
600 MONTGOMERY STREET, SUITE 4500		
(Street)		
SAN FRANCISCO	CA	94111
(City)	(State)	(Zip)

Explanation of Responses:

- Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021.
- These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"), Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
- In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .

[/s/ Dennis Ryan on behalf of FS Development Holdings, LLC](#) [02/09/2021](#)
[/s/ Dennis Ryan on behalf of Foresite Capital Fund V, L.P.](#) [02/09/2021](#)
[/s/ Dennis Ryan on behalf of Foresite Capital Management V, LLC](#) [02/09/2021](#)
[/s/ Dennis Ryan on behalf of Foresite Capital Opportunity Fund V, L.P.](#) [02/09/2021](#)
[/s/ Dennis Ryan on behalf of Foresite Capital Opportunity Management V, LLC](#) [02/09/2021](#)
[/s/ Dennis Ryan as Attorney-in-Fact](#) [02/09/2021](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.